A sensitive guanine-based DNA-biosensor to monitor Cabozantinib anticancer in biological samples

Key Points

• The biosensor effectively measures cabozantinib levels in biological samples, supporting its role in monitoring anticancer therapy.
• Key evidence indicates that the guanine-based approach yields a high sensitivity for detecting cabozantinib, enhancing clinical relevance.
• Assessment using a novel dna-biosensor demonstrates reliable monitoring of cabozantinib in varied biological samples for therapeutic use.
• This work highlights the potential for improved cancer treatment management using biosensors, with further validation needed in diverse populations.